Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Metabolic dysfunction-associated steatotic liver disease (MASLD)—previously known as "non-alcoholic fatty liver ...

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), ...

Blocking the enzyme ACMSD can significantly reduce damage caused by metabolic liver disease according to a new study.

Genflow Biosciences PLC on Tuesday said it has secured EUR4 million in funding from the Wallonia region in Belgium, to support its gene therapy development work. The London-based biotechnology company ...